SUMOylation in carcinogenesis

Cancer Letters

Volumn 316, Issue 2, 2012, Pages 113-125

  Bettermann, Kira ^a   Benesch, Martin ^a   Weis, Serge ^b   Haybaeck, Johannes ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

Cancer; SUMO; Ubiquitin

Indexed keywords

BINDING PROTEIN; HISTONE DEACETYLASE; POLYCOMB 2 PROTEIN; POLYCOMB GROUP PROTEIN; PROTEIN P53; PROTEIN RANBP2; PROTEIN SENP1; PROTEIN SENP2; PROTEIN SENP3; PROTEIN SENP5; PROTEIN SENP6; PROTEIN SENP7; REGULATOR PROTEIN; SUMO PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BINDING AFFINITY; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; CONGESTIVE CARDIOMYOPATHY; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SHORT SURVEY; SIGNAL TRANSDUCTION; SPINOCEREBELLAR DEGENERATION; SUMOYLATION; TUMOR PROMOTION;

MAMMALIA;

EID: 84856046085     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.036     Document Type: Review

References (238)

1. Kim K.I., Baek S.H., Jeon Y.J., Nishimori S., Suzuki T., Uchida S., Shimbara N., Saitoh H., Tanaka K., Chung C.H. A new SUMO-1-specific protease, SUSP1, that is highly expressed in reproductive organs. J. Biol. Chem. 2000, 275:14102-14106.
2. Tatham M.H., Jaffray E., Vaughan O.A., Desterro J.M., Botting C.H., Naismith J.H., Hay R.T. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 2001, 276:35368-35374.
3. Wilson V.G. SUMO Regulation of Cellular Processes 2009, Springer.
4. Bayer P., Arndt A., Metzger S., Mahajan R., Melchior F., Jaenicke R., Becker J. Structure determination of the small ubiquitin-related modifier SUMO-1. J. Mol. Biol. 1998, 280:275-286.
5. Bernier-Villamor V., Sampson D.A., Matunis M.J., Lima C.D. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 2002, 108:345-356.
6. Mossessova E., Lima C.D. Ulp1-SUMO crystal structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. Mol. Cell. 2000, 5:865-876.
7. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell. Biol. 2007, 8:947-956.
8. Mahajan R., Delphin C., Guan T., Gerace L., Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 1997, 88:97-107.
9. Matunis M.J., Coutavas E., Blobel G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 1996, 135:1457-1470.
10. Gill G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms?. Genes Dev. 2004, 18:2046-2059.
11. Gill G. Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr. Opin. Genet. Dev. 2003, 13:108-113.
12. Goodson M.L., Hong Y., Rogers R., Matunis M.J., Park-Sarge O.K., Sarge K.D. Sumo-1 modification regulates the DNA binding activity of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated transcription factor. J. Biol. Chem. 2001, 276:18513-18518.
13. Hong Y., Rogers R., Matunis M.J., Mayhew C.N., Goodson M.L., Park-Sarge O.K., Sarge K.D. Regulation of heat shock transcription factor 1 by stress-induced SUMO-1 modification. J. Biol. Chem. 2001, 276:40263-40267.
14. Deyrieux A.F., Rosas-Acosta G., Ozbun M.A., Wilson V.G. Sumoylation dynamics during keratinocyte differentiation. J. Cell Sci. 2007, 120:125-136.
15. Gill G. SUMO changes Sox for developmental diversity. Mol. Cell. 2005, 20:495-496.
16. Ihara M., Koyama H., Uchimura Y., Saitoh H., Kikuchi A. Noncovalent binding of small ubiquitin-related modifier (SUMO) protease to SUMO is necessary for enzymatic activities and cell growth. J. Biol. Chem. 2007, 282:16465-16475.
17. Alkuraya F.S., Saadi I., Lund J.J., Turbe-Doan A., Morton C.C., Maas R.L. SUMO1 haploinsufficiency leads to cleft lip and palate. Science 2006, 313:1751.
18. Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., Novotny M., Slamon D.J., Plowman G.D. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998, 17:3052-3065.
19. Klein U.R., Haindl M., Nigg E.A., Muller S. RanBP2 and SENP3 function in a mitotic SUMO2/3 conjugation-deconjugation cycle on Borealin. Mol. Biol. Cell 2009, 20:410-418.
20. Yang W., Paschen W. Gene expression and cell growth are modified by silencing SUMO2 and SUMO3 expression. Biochem. Biophys. Res. Commun. 2009, 382:215-218.
21. Bohren K.M., Nadkarni V., Song J.H., Gabbay K.H., Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem. 2004, 279:27233-27238.
22. Guo D., Li M., Zhang Y., Yang P., Eckenrode S., Hopkins D., Zheng W., Purohit S., Podolsky R.H., Muir A., Wang J., Dong Z., Brusko T., Atkinson M., Pozzilli P., Zeidler A., Raffel L.J., Jacob C.O., Park Y., Serrano-Rios M., Larrad M.T., Zhang Z., Garchon H.J., Bach J.F., Rotter J.I., She J.X., Wang C.Y. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat. Genet. 2004, 36:837-841.
23. Johnson E.S. Protein modification by SUMO. Annu. Rev. Biochem. 2004, 73:355-382.
24. Desterro J.M., Thomson J., Hay R.T. Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett. 1997, 417:297-300.
25. Hayashi T., Seki M., Maeda D., Wang W., Kawabe Y., Seki T., Saitoh H., Fukagawa T., Yagi H., Enomoto T. Ubc9 is essential for viability of higher eukaryotic cells. Exp. Cell Res. 2002, 280:212-221.
26. Johnson E.S., Blobel G. Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J. Biol. Chem. 1997, 272:26799-26802.
27. Hochstrasser M. SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 2001, 107:5-8.
28. Aravind L., Koonin E.V. SAP - a putative DNA-binding motif involved in chromosomal organization. Trends Biochem. Sci. 2000, 25:112-114.
29. Kipp M., Gohring F., Ostendorp T., van Drunen C.M., van Driel R., Przybylski M., Fackelmayer F.O. SAF-Box, a conserved protein domain that specifically recognizes scaffold attachment region DNA. Mol. Cell. Biol. 2000, 20:7480-7489.
30. Sachdev S., Bruhn L., Sieber H., Pichler A., Melchior F., Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 2001, 15:3088-3103.
31. Sharrocks A.D. PIAS proteins and transcriptional regulation - more than just SUMO E3 ligases?. Genes Dev. 2006, 20:754-758.
32. Tan J.A., Hall S.H., Hamil K.G., Grossman G., Petrusz P., French F.S. Protein inhibitors of activated STAT resemble scaffold attachment factors and function as interacting nuclear receptor coregulators. J. Biol. Chem. 2002, 277:16993-17001.
33. Kahyo T., Nishida T., Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell. 2001, 8:713-718.
34. Kotaja N., Karvonen U., Janne O.A., Palvimo J.J. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cell. Biol. 2002, 22:5222-5234.
35. Nakagawa K., Yokosawa H. PIAS3 induces SUMO-1 modification and transcriptional repression of IRF-1. FEBS Lett. 2002, 530:204-208.
36. Nishida T., Yasuda H. PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J. Biol. Chem. 2002, 277:41311-41317.
37. Sapetschnig A., Rischitor G., Braun H., Doll A., Schergaut M., Melchior F., Suske G. Transcription factor Sp3 is silenced through SUMO modification by PIAS1. EMBO J. 2002, 21:5206-5215.
38. Schmidt D., Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A 2002, 99:2872-2877.
39. Gareau J.R., Lima C.D. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell. Biol. 2010, 11:861-871.
40. Miyauchi Y., Yogosawa S., Honda R., Nishida T., Yasuda H. Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes. J. Biol. Chem. 2002, 277:50131-50136.
41. Johnson E.S., Gupta A.A. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 2001, 106:735-744.
42. Takahashi Y., Toh-e A., Kikuchi Y. A novel factor required for the SUMO1/Smt3 conjugation of yeast septins. Gene 2001, 275:223-231.
43. Yunus A.A., Lima C.D. Structure of the Siz/PIAS SUMO E3 ligase Siz1 and determinants required for SUMO modification of PCNA. Mol. Cell. 2009, 35:669-682.
44. Kerscher O. SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep. 2007, 8:550-555.
45. Perry J.J., Tainer J.A., Boddy M.N. A SIM-ultaneous role for SUMO and ubiquitin. Trends Biochem. Sci. 2008, 33:201-208.
46. Lois L.M., Lima C.D. Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J. 2005, 24:439-451.
47. Olsen S.K., Capili A.D., Lu X., Tan D.S., Lima C.D. Active site remodelling accompanies thioester bond formation in the SUMO E1. Nature 2010, 463:906-912.
48. Gregoire S., Yang X.J. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Mol. Cell. Biol. 2005, 25:2273-2287.
49. Hietakangas V., Ahlskog J.K., Jakobsson A.M., Hellesuo M., Sahlberg N.M., Holmberg C.I., Mikhailov A., Palvimo J.J., Pirkkala L., Sistonen L. Phosphorylation of serine 303 is a prerequisite for the stress-inducible SUMO modification of heat shock factor 1. Mol Cell Biol 2003, 23:2953-2968.
50. Hietakangas V., Anckar J., Blomster H.A., Fujimoto M., Palvimo J.J., Nakai A., Sistonen L. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc Natl Acad Sci U S A 2006, 103:45-50.
51. Pichler A., Gast A., Seeler J.S., Dejean A., Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002, 108:109-120.
52. Kirsh O., Seeler J.S., Pichler A., Gast A., Muller S., Miska E., Mathieu M., Harel-Bellan A., Kouzarides T., Melchior F., Dejean A. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J. 2002, 21:2682-2691.
53. Tatham M.H., Kim S., Jaffray E., Song J., Chen Y., Hay R.T. Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection. Nat. Struct. Mol. Biol. 2005, 12:67-74.
54. Dawlaty M.M., Malureanu L., Jeganathan K.B., Kao E., Sustmann C., Tahk S., Shuai K., Grosschedl R., van Deursen J.M. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell 2008, 133:103-115.
55. Dahiya A., Wong S., Gonzalo S., Gavin M., Dean D.C. Linking the Rb and polycomb pathways. Mol. Cell. 2001, 8:557-569.
56. Ogawa H., Ishiguro K., Gaubatz S., Livingston D.M., Nakatani Y. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science 2002, 296:1132-1136.
57. Kagey M.H., Melhuish T.A., Wotton D. The polycomb protein Pc2 is a SUMO E3. Cell 2003, 113:127-137.
58. Czermin B., Melfi R., McCabe D., Seitz V., Imhof A., Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 2002, 111:185-196.
59. Kuzmichev A., Nishioka K., Erdjument-Bromage H., Tempst P., Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 2002, 16:2893-2905.
60. Kagey M.H., Melhuish T.A., Powers S.E., Wotton D. Multiple activities contribute to Pc2 E3 function. EMBO J. 2005, 24:108-119.
61. Yeh E.T. SUMOylation and De-SUMOylation: wrestling with life's processes. J. Biol. Chem. 2009, 284:8223-8227.
62. Li S.J., Hochstrasser M. A new protease required for cell-cycle progression in yeast. Nature 1999, 398:246-251.
63. Li S.J., Hochstrasser M. The yeast ULP2 (SMT4) gene encodes a novel protease specific for the ubiquitin-like Smt3 protein. Mol. Cell. Biol. 2000, 20:2367-2377.
64. Takahashi Y., Mizoi J., Toh E.A., Kikuchi Y. Yeast Ulp1, an Smt3-specific protease, associates with nucleoporins. J. Biochem. 2000, 128:723-725.
65. Panse V.G., Kuster B., Gerstberger T., Hurt E. Unconventional tethering of Ulp1 to the transport channel of the nuclear pore complex by karyopherins. Nat. Cell. Biol. 2003, 5:21-27.
66. Schwienhorst I., Johnson E.S., Dohmen R.J. SUMO conjugation and deconjugation. Mol. Gen. Genet. 2000, 263:771-786.
67. Strunnikov A.V., Aravind L., Koonin E.V. Saccharomyces cerevisiae SMT4 encodes an evolutionarily conserved protease with a role in chromosome condensation regulation. Genetics 2001, 158:95-107.
68. Li S.J., Hochstrasser M. The Ulp1 SUMO isopeptidase: distinct domains required for viability, nuclear envelope localization, and substrate specificity. J. Cell. Biol. 2003, 160:1069-1081.
69. Wang Y., Dasso M. SUMOylation and deSUMOylation at a glance. J. Cell Sci. 2009, 122:4249-4252.
70. Wilkinson K.A., Henley J.M. Mechanisms, regulation and consequences of protein SUMOylation. Biochem. J. 2010, 428:133-145.
71. Di Bacco A., Ouyang J., Lee H.Y., Catic A., Ploegh H., Gill G. The SUMO-specific protease SENP5 is required for cell division. Mol. Cell. Biol. 2006, 26:4489-4498.
72. Gong L., Yeh E.T. Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J. Biol. Chem. 2006, 281:15869-15877.
73. Hang J., Dasso M. Association of the human SUMO-1 protease SENP2 with the nuclear pore. J. Biol. Chem. 2002, 277:19961-19966.
74. Zhang H., Saitoh H., Matunis M.J. Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol. Cell. Biol. 2002, 22:6498-6508.
75. Nishida T., Tanaka H., Yasuda H. A novel mammalian Smt3-specific isopeptidase 1 (SMT3IP1) localized in the nucleolus at interphase. Eur. J. Biochem. 2000, 267:6423-6427.
76. Zunino R., Schauss A., Rippstein P., Andrade-Navarro M., McBride H.M. The SUMO protease SENP5 is required to maintain mitochondrial morphology and function. J. Cell Sci. 2007, 120:1178-1188.
77. Gong L., Millas S., Maul G.G., Yeh E.T. Differential regulation of sentrinized proteins by a novel sentrin-specific protease. J. Biol. Chem. 2000, 275:3355-3359.
78. Bailey D., O'Hare P. Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J. Biol. Chem. 2004, 279:692-703.
79. Kim Y.H., Sung K.S., Lee S.J., Kim Y.O., Choi C.Y., Kim Y. Desumoylation of homeodomain-interacting protein kinase 2 (HIPK2) through the cytoplasmic-nuclear shuttling of the SUMO-specific protease SENP1. FEBS Lett. 2005, 579:6272-6278.
80. Melchior F., Schergaut M., Pichler A. SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 2003, 28:612-618.
81. K.O. Alegre, and D. Reverter, Swapping the SUMO isoform specificity of SUMO proteases SENP6 and SENP7, J. Biol. Chem. (2011).
82. Kim J.H., Baek S.H. Emerging roles of desumoylating enzymes. Biochim. Biophys. Acta 2009, 1792:155-162.
83. Shen L.N., Dong C., Liu H., Naismith J.H., Hay R.T. The structure of SENP1-SUMO-2 complex suggests a structural basis for discrimination between SUMO paralogues during processing. Biochem. J. 2006, 397:279-288.
84. Xu Z., Au S.W. Mapping residues of SUMO precursors essential in differential maturation by SUMO-specific protease, SENP1. Biochem. J. 2005, 386:325-330.
85. Arnaoutov A., Dasso M. The Ran GTPase regulates kinetochore function. Dev. Cell. 2003, 5:99-111.
86. Quimby B.B., Dasso M. The small GTPase Ran: interpreting the signs. Curr. Opin. Cell. Biol. 2003, 15:338-344.
87. Walther T.C., Askjaer P., Gentzel M., Habermann A., Griffiths G., Wilm M., Mattaj I.W., Hetzer M. RanGTP mediates nuclear pore complex assembly. Nature 2003, 424:689-694.
88. Shen T.H., Lin H.K., Scaglioni P.P., Yung T.M., Pandolfi P.P. The mechanisms of PML-nuclear body formation. Mol. Cell. 2006, 24:331-339.
89. Best J.L., Ganiatsas S., Agarwal S., Changou A., Salomoni P., Shirihai O., Meluh P.B., Pandolfi P.P., Zon L.I. SUMO-1 protease-1 regulates gene transcription through PML. Mol. Cell. 2002, 10:843-855.
90. Han Y., Huang C., Sun X., Xiang B., Wang M., Yeh E.T., Chen Y., Li H., Shi G., Cang H., Sun Y., Wang J., Wang W., Gao F., Yi J. SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J. Biol. Chem. 2010, 285:12906-12915.
91. Hattersley N., Shen L., Jaffray E.G., Hay R.T. The SUMO protease SENP6 is a direct regulator of PML nuclear bodies. Mol. Biol. Cell 2011, 22:78-90.
92. Mukhopadhyay D., Ayaydin F., Kolli N., Tan S.H., Anan T., Kametaka A., Azuma Y., Wilkinson K.D., Dasso M. SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. J. Cell Biol. 2006, 174:939-949.
93. Ohbayashi N., Kawakami S., Muromoto R., Togi S., Ikeda O., Kamitani S., Sekine Y., Honjoh T., Matsuda T. The IL-6 family of cytokines modulates STAT3 activation by desumoylation of PML through SENP1 induction. Biochem. Biophys. Res. Commun. 2008, 371:823-828.
94. Shen L.N., Geoffroy M.C., Jaffray E.G., Hay R.T. Characterization of SENP7, a SUMO-2/3-specific isopeptidase. Biochem. J. 2009, 421:223-230.
95. Cheng J., Wang D., Wang Z., Yeh E.T. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol. Cell. Biol. 2004, 24:6021-6028.
96. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 2002, 20:3001-3015.
97. McKenna N.J., O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002, 108:465-474.
98. Bawa-Khalfe T., Cheng J., Wang Z., Yeh E.T. Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J. Biol. Chem. 2007, 282:37341-37349.
99. Poukka H., Karvonen U., Janne O.A., Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 2000, 97:14145-14150.
100. Cheng J., Bawa T., Lee P., Gong L., Yeh E.T. Role of desumoylation in the development of prostate cancer. Neoplasia 2006, 8:667-676.
101. Li X., Luo Y., Yu L., Lin Y., Luo D., Zhang H., He Y., Kim Y.O., Kim Y., Tang S., Min W. SENP1 mediates TNF-induced desumoylation and cytoplasmic translocation of HIPK1 to enhance ASK1-dependent apoptosis. Cell. Death Differ. 2008, 15:739-750.
102. Cheng J., Kang X., Zhang S., Yeh E.T. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 2007, 131:584-595.
103. Kadoya T., Yamamoto H., Suzuki T., Yukita A., Fukui A., Michiue T., Asahara T., Tanaka K., Asashima M., Kikuchi A. Desumoylation activity of Axam, a novel Axin-binding protein, is involved in downregulation of beta-catenin. Mol. Cell. Biol. 2002, 22:3803-3819.
104. Nishida T., Kaneko F., Kitagawa M., Yasuda H. Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat axam, which is an axin-binding protein promoting beta-catenin degradation. J. Biol. Chem. 2001, 276:39060-39066.
105. Choi S.J., Chung S.S., Rho E.J., Lee H.W., Lee M.H., Choi H.S., Seol J.H., Baek S.H., Bang O.S., Chung C.H. Negative modulation of RXRalpha transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1. J. Biol. Chem. 2006, 281:30669-30677.
106. Sehat B., Andersson S., Vasilcanu R., Girnita L., Larsson O. Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS One 2007, 2:e340.
107. Kang J.S., Saunier E.F., Akhurst R.J., Derynck R. The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat. Cell. Biol. 2008, 10:654-664.
108. Grigoletto A., Lestienne P., Rosenbaum J. The multifaceted proteins Reptin and Pontin as major players in cancer. Biochim. Biophys. Acta 2011, 1815:147-157.
109. Fernandez-Miranda G., Perez de Castro I., Carmena M., Aguirre-Portoles C., Ruchaud S., Fant X., Montoya G., Earnshaw W.C., Malumbres M. SUMOylation modulates the function of Aurora-B kinase. J. Cell Sci. 2010, 123:2823-2833.
110. Galanty Y., Belotserkovskaya R., Coates J., Polo S., Miller K.M., Jackson S.P. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009, 462:935-939.
111. Kim J.H., Choi H.J., Kim B., Kim M.H., Lee J.M., Kim I.S., Lee M.H., Choi S.J., Kim K.I., Kim S.I., Chung C.H., Baek S.H. Roles of sumoylation of a reptin chromatin-remodelling complex in cancer metastasis. Nat. Cell. Biol. 2006, 8:631-639.
112. Lallemand-Breitenbach V., Jeanne M., Benhenda S., Nasr R., Lei M., Peres L., Zhou J., Zhu J., Raught B. And H. de The, Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell. Biol. 2008, 10:547-555.
113. Park M.A., Seok Y.J., Jeong G., Lee J.S. SUMO1 negatively regulates BRCA1-mediated transcription, via modulation of promoter occupancy. Nucl. Acids Res. 2008, 36:263-283.
114. Ryu H., Al-Ani G., Deckert K., Kirkpatrick D., Gygi S.P., Dasso M., Azuma Y. PIASy mediates SUMO-2/3 conjugation of poly(ADP-ribose) polymerase 1 (PARP1) on mitotic chromosomes. J. Biol. Chem. 2010, 285:14415-14423.
115. Sehat B., Tofigh A., Lin Y., Trocme E., Liljedahl U., Lagergren J., Larsson O. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci. Signal 2010, 3:ra10.
116. Sentis S., Le Romancer M., Bianchin C., Rostan M.C., Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol. Endocrinol. 2005, 19:2671-2684.
117. Smolen G.A., Vassileva M.T., Wells J., Matunis M.J., Haber D.A. SUMO-1 modification of the Wilms' tumor suppressor WT1. Cancer Res 2004, 64:7846-7851.
118. Stehmeier P., Muller S. Regulation of p53 family members by the ubiquitin-like SUMO system. DNA Repair (Amst) 2009, 8:491-498.
119. Vialter A., Vincent A., Demidem A., Morvan D., Stepien G., Venezia N.D., Rio P.G. Cell cycle-dependent conjugation of endogenous BRCA1 protein with SUMO-2/3. Biochim. Biophys. Acta 2011, 1810:432-438.
120. X. Xu, J. Vatsyayan, C. Gao, C.J. Bakkenist, and J. Hu, Sumoylation of eIF4E activates mRNA translation, EMBO Rep 11, 299-304.
121. Yang Y., Tse A.K., Li P., Ma Q., Xiang S., Nicosia S.V., Seto E., Zhang X., Bai W. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. Oncogene 2011, 30:2207-2218.
122. Zhang X.W., Yan X.J., Zhou Z.R., Yang F.F., Wu Z.Y., Sun H.B., Liang W.X., Song A.X., Lallemand-Breitenbach V., Jeanne M., Zhang Q.Y., Yang H.Y., Huang Q.H., Zhou G.B., Tong J.H., Zhang Y., Wu J.H., Hu H.Y., de The H., Chen S.J., Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010, 328:240-243.
123. Lee S.L., Choi H.J., S.H., Baek Sumoylation and its contribution to cancer. SUMO Regulation of Cellular Processes 2009, 253-272. Springer. V.G. Wilson (Ed.).
124. Faus H., Haendler B. Post-translational modifications of steroid receptors. Biomed. Pharmacother. 2006, 60:520-528.
125. Ihara M., Yamamoto H., Kikuchi A. SUMO-1 modification of PIASy, an E3 ligase, is necessary for PIASy-dependent activation of Tcf-4. Mol. Cell. Biol. 2005, 25:3506-3518.
126. Mabb A.M., Miyamoto S. SUMO and NF-kappaB ties. Cell. Mol. Life Sci. 2007, 64:1979-1996.
127. Yamamoto H., Ihara M., Matsuura Y., Kikuchi A. Sumoylation is involved in beta-catenin-dependent activation of Tcf-4. EMBO J. 2003, 22:2047-2059.
128. Orr H.T., Zoghbi H.Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 2007, 30:575-621.
129. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
130. Steffan J.S., Agrawal N., Pallos J., Rockabrand E., Trotman L.C., Slepko N., Illes K., Lukacsovich T., Zhu Y.Z., Cattaneo E., Pandolfi P.P., Thompson L.M., Marsh J.L. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
131. Subramaniam S., Sixt K.M., Barrow R., Snyder S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
132. Lee G., Thangavel R., Sharma V.M., Litersky J.M., Bhaskar K., Fang S.M., Do L.H., Andreadis A., Van Hoesen G., Ksiezak-Reding H. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J. Neurosci. 2004, 24:2304-2312.
133. Dorval V., Fraser P.E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J. Biol. Chem. 2006, 281:9919-9924.
134. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
135. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314:777-781.
136. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8:499-509.
137. Zhang Y.Q., Sarge K.D. Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels. Biochem. Biophys. Res. Commun. 2008, 374:673-678.
138. Dorval V., Mazzella M.J., Mathews P.M., Hay R.T., Fraser P.E. Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins. Biochem. J. 2007, 404:309-316.
139. Li Y., Wang H., Wang S., Quon D., Liu Y.W., Cordell B. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc Natl Acad Sci U S A 2003, 100:259-264.
140. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
141. Hedrich K., Djarmati A., Schafer N., Hering R., Wellenbrock C., Weiss P.H., Hilker R., Vieregge P., Ozelius L.J., Heutink P., Bonifati V., Schwinger E., Lang A.E., Noth J., Bressman S.B., Pramstaller P.P., Riess O., Klein C. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 2004, 62:389-394.
142. Shinbo Y., Niki T., Taira T., Ooe H., Takahashi-Niki K., Maita C., Seino C., Iguchi-Ariga S.M., Ariga H. Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell. Death Differ. 2006, 13:96-108.
143. Takahashi K., Taira T., Niki T., Seino C., Iguchi-Ariga S.M., Ariga H. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J. Biol. Chem. 2001, 276:37556-37563.
144. Zhong N., Kim C.Y., Rizzu P., Geula C., Porter D.R., Pothos E.N., Squitieri F., Heutink P., Xu J. DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J. Biol. Chem. 2006, 281:20940-20948.
145. Zhong N., Xu J. Synergistic activation of the human MnSOD promoter by DJ-1 and PGC-1alpha: regulation by SUMOylation and oxidation. Hum. Mol. Genet. 2008, 17:3357-3367.
146. Riley B.E., Zoghbi H.Y., Orr H.T. SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J. Biol. Chem. 2005, 280:21942-21948.
147. Ryu J., Cho S., Park B.C., Lee do H. Oxidative stress-enhanced SUMOylation and aggregation of ataxin-1: implication of JNK pathway. Biochem. Biophys. Res. Commun. 2010, 393:280-285.
148. Fei E., Jia N., Yan M., Ying Z., Sun Q., Wang H., Zhang T., Ma X., Ding H., Yao X., Shi Y., Wang G. SUMO-1 modification increases human SOD1 stability and aggregation. Biochem. Biophys. Res. Commun. 2006, 347:406-412.
149. Broers J.L., Ramaekers F.C., Bonne G., Yaou R.B., Hutchison C.J. Nuclear lamins: laminopathies and their role in premature ageing. Physiol. Rev. 2006, 86:967-1008.
150. Capell B.C., Collins F.S. Human laminopathies: nuclei gone genetically awry. Nat. Rev. Genet. 2006, 7:940-952.
151. Mattout A., Dechat T., Adam S.A., Goldman R.D., Gruenbaum Y. Nuclear lamins, diseases and aging. Curr. Opin. Cell. Biol. 2006, 18:335-341.
152. Parnaik V.K., Manju K. Laminopathies: multiple disorders arising from defects in nuclear architecture. J. Biosci. 2006, 31:405-421.
153. Zhang Y.Q., Sarge K.D. Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies. J. Cell Biol. 2008, 182:35-39.
154. Onengut-Gumuscu S., Concannon P. Mapping genes for autoimmunity in humans: type 1 diabetes as a model. Immunol. Rev. 2002, 190:182-194.
155. Owerbach D., McKay E.M., Yeh E.T., Gabbay K.H., Bohren K.M. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem. Biophys. Res. Commun. 2005, 337:517-520.
156. Zhang F.P., Mikkonen L., Toppari J., Palvimo J.J., Thesleff I., Janne O.A. Sumo-1 function is dispensable in normal mouse development. Mol. Cell. Biol. 2008, 28:5381-5390.
157. Bartek J., Hodny Z. SUMO boosts the DNA damage response barrier against cancer. Cancer Cell 2010, 17:9-11.
158. Bergink S., Jentsch S. Principles of ubiquitin and SUMO modifications in DNA repair. Nature 2009, 458:461-467.
159. Branzei D., Foiani M. Regulation of DNA repair throughout the cell cycle. Nat. Rev. Mol. Cell. Biol. 2008, 9:297-308.
160. Dunnebier T., Bermejo J.L., Haas S., Fischer H.P., Pierl C.B., Justenhoven C., Brauch H., Baisch C., Gilbert M., Harth V., Spickenheuer A., Rabstein S., Pesch B., Bruning T., Ko Y.D., Hamann U. Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade. Int. J. Cancer 2009, 125:596-602.
161. Synowiec E., Krupa R., Morawiec Z., Wasylecka M., Dziki L., Morawiec J., Blasiak J., Wozniak K. Efficacy of DNA double-strand breaks repair in breast cancer is decreased in carriers of the variant allele of the UBC9 gene c.73G>A polymorphism. Mutat. Res. 2010, 694:31-38.
162. Morris J.R., Boutell C., Keppler M., Densham R., Weekes D., Alamshah A., Butler L., Galanty Y., Pangon L., Kiuchi T., Ng T., Solomon E. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009, 462:886-890.
163. Brady C.A., Attardi L.D. P53 at a glance. J. Cell Sci. 2010, 123:2527-2532.
164. Bode A.M., Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 2004, 4:793-805.
165. Hollstein M., Hainaut P. Massively regulated genes: the example of TP53. J. Pathol. 2010, 220:164-173.
166. Meek D.W.a., Anderson C.W. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harbor Perspect. Biol. 2009, 1:1-16.
167. Mendrysa S.M., Perry M.E. The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. Mol. Cell. Biol. 2000, 20:2023-2030.
168. Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., Scheffner M., Del Sal G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 1999, 18:6462-6471.
169. Rodriguez M.S., Desterro J.M., Lain S., Midgley C.A., Lane D.P., Hay R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 1999, 18:6455-6461.
170. Muller S., Berger M., Lehembre F., Seeler J.S., Haupt Y., Dejean A. C-Jun and p53 activity is modulated by SUMO-1 modification. J. Biol. Chem. 2000, 275:13321-13329.
171. Kwek S.S., Derry J., Tyner A.L., Shen Z., Gudkov A.V. Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene 2001, 20:2587-2599.
172. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
173. Chen L., Chen J. MDM2-ARF complex regulates p53 sumoylation. Oncogene 2003, 22:5348-5357.
174. Xirodimas D.P., Chisholm J., Desterro J.M., Lane D.P., Hay R.T. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett. 2002, 528:207-211.
175. Lee M.H., Lee S.W., Lee E.J., Choi S.J., Chung S.S., Lee J.I., Cho J.M., Seol J.H., Baek S.H., Kim K.I., Chiba T., Tanaka K., Bang O.S., Chung C.H. SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat. Cell Biol. 2006, 8:1424-1431.
176. Sarge K.D., Park-Sarge O.K. SUMO and its role in human diseases. Int. Rev. Cell. Mol. Biol. 2011, 288:167-183.
177. Bossis G., Malnou C.E., Farras R., Andermarcher E., Hipskind R., Rodriguez M., Schmidt D., Muller S., Jariel-Encontre I., Piechaczyk M. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol. Cell. Biol. 2005, 25:6964-6979.
178. Cheng J., Perkins N.D., Yeh E.T. Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J. Biol. Chem. 2005, 280:14492-14498.
179. Haybaeck J., Zeller N., Wolf M.J., Weber A., Wagner U., Kurrer M.O., Bremer J., Iezzi G., Graf R., Clavien P.A., Thimme R., Blum H., Nedospasov S.A., Zatloukal K., Ramzan M., Ciesek S., Pietschmann T., Marche P.N., Karin M., Kopf M., Browning J.L., Aguzzi A., Heikenwalder M. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009, 16:295-308.
180. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
181. Desterro J.M., Rodriguez M.S., Hay R.T. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol. Cell. 1998, 2:233-239.
182. Bettermann K., Vucur M., Haybaeck J., Koppe C., Janssen J., Heymann F., Weber A., Weiskirchen R., Liedtke C., Gassler N., Muller M., de Vos R., Wolf M.J., Boege Y., Seleznik G.M., Zeller N., Erny D., Fuchs T., Zoller S., Cairo S., Buendia M.A., Prinz M., Akira S., Tacke F., Heikenwalder M., Trautwein C., Luedde T. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 2010, 17:481-496.
183. Yang Y., Xia F., Hermance N., Mabb A., Simonson S., Morrissey S., Gandhi P., Munson M., Miyamoto S., Kelliher M.A. A cytosolic ATM/NEMO/RIP1
184. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
185. Huang T.T., Wuerzberger-Davis S.M., Wu Z.H., Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 2003, 115:565-576.
186. Mo Y.Y., Moschos S.J. Targeting Ubc9 for cancer therapy. Expert. Opin. Ther. Targets 2005, 9:1203-1216.
187. Mo Y.Y., Yu Y., Theodosiou E., Ee P.L., Beck W.T. A role for Ubc9 in tumorigenesis. Oncogene 2005, 24:2677-2683.
188. Doniels-Silvers A.L., Nimri C.F., Stoner G.D., Lubet R.A., You M. Differential gene expression in human lung adenocarinomas and squamous cell carcinomas. Clin. Cancer Res. 2002, 8:1127-1138.
189. Jacques C., Baris O., Prunier-Mirebeau D., Savagner F., Rodien P., Rohmer V., Franc B., Guyetant S., Malthiery Y., Reynier P. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J. Clin. Endocrinol. Metab. 2005, 90:2314-2320.
190. Xu Y., Li J., Zuo Y., Deng J., Wang L.S., Chen G.Q. SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors. Cancer Lett 2011, 309:78-84.
191. Driscoll J.J., Pelluru D., Lefkimmiatis K., Fulciniti M., Prabhala R.H., Greipp P.R., Barlogie B., Tai Y.T., Anderson K.C., Shaughnessy J.D., Annunziata C.M., Munshi N.C. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood 2010, 115:2827-2834.
192. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
193. Kim Y.B., Ki S.W., Yoshida M., Horinouchi S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J. Antibiot. (Tokyo) 2000, 53:1191-1200.
194. Mai A., Massa S., Rotili D., Cerbara I., Valente S., Pezzi R., Simeoni S., Ragno R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 2005, 25:261-309.
195. Geng L., Cuneo K.C., Fu A., Tu T., Atadja P.W., Hallahan D.E. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006, 66:11298-11304.
196. Qian D.Z., Kato Y., Shabbeer S., Wei Y., Verheul H.M., Salumbides B., Sanni T., Atadja P., Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 2006, 12:634-642.
197. Yang X.J., Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007, 26:5310-5318.
198. Gao L., Cueto M.A., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 2002, 277:25748-25755.
199. Bouras T., Fu M., Sauve A.A., Wang F., Quong A.A., Perkins N.D., Hay R.T., Gu W., Pestell R.G. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J. Biol. Chem. 2005, 280:10264-10276.
200. Girdwood D., Bumpass D., Vaughan O.A., Thain A., Anderson L.A., Snowden A.W., Garcia-Wilson E., Perkins N.D., Hay R.T. P300 transcriptional repression is mediated by SUMO modification. Mol. Cell. 2003, 11:1043-1054.
201. Jacobs A.M., Nicol S.M., Hislop R.G., Jaffray E.G., Hay R.T., Fuller-Pace F.V. SUMO modification of the DEAD box protein p68 modulates its transcriptional activity and promotes its interaction with HDAC1. Oncogene 2007, 26:5866-5876.
202. Yang S.H., Sharrocks A.D. SUMO promotes HDAC-mediated transcriptional repression. Mol. Cell. 2004, 13:611-617.
203. Yang S.H., Sharrocks A.D. PIASx acts as an Elk-1 coactivator by facilitating derepression. EMBO J. 2005, 24:2161-2171.
204. Zhao X., Sternsdorf T., Bolger T.A., Evans R.M., Yao T.P. Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Mol. Cell. Biol. 2005, 25:8456-8464.
205. Wu S.Y., Chiang C.M. Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J. 2009, 28:1246-1259.
206. Gao C., Ho C.C., Reineke E., Lam M., Cheng X., Stanya K.J., Liu Y., Chakraborty S., Shih H.M., Kao H.Y. Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation. Mol. Cell. Biol. 2008, 28:5658-5667.
207. Ling Y., Sankpal U.T., Robertson A.K., McNally J.G., Karpova T., Robertson K.D. Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription. Nucl. Acids Res. 2004, 32:598-610.
208. Shan S.F., Wang L.F., Zhai J.W., Qin Y., Ouyang H.F., Kong Y.Y., Liu J., Wang Y., Xie Y.H. Modulation of transcriptional corepressor activity of prospero-related homeobox protein (Prox1) by SUMO modification. FEBS Lett. 2008, 582:3723-3728.
209. Gross M., Yang R., Top I., Gasper C., Shuai K. PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene 2004, 23:3059-3066.
210. Kuo H.Y., Chang C.C., Jeng J.C., Hu H.M., Lin D.Y., Maul G.G., Kwok R.P., Shih H.M. SUMO modification negatively modulates the transcriptional activity of CREB-binding protein via the recruitment of Daxx. Proc Natl Acad Sci U S A 2005, 102:16973-16978.
211. Tussie-Luna M.I., Bayarsaihan D., Seto E., Ruddle F.H., Roy A.L. Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta. Proc Natl Acad Sci U S A 2002, 99:12807-12812.
212. Hoeller D., Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009, 458:438-444.
213. Tatham M.H., Geoffroy M.C., Shen L., Plechanovova A., Hattersley N., Jaffray E.G., Palvimo J.J., Hay R.T. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell. Biol. 2008, 10:538-546.
214. Martin S.F., Hattersley N., Samuel I.D., Hay R.T., Tatham M.H. A fluorescence-resonance-energy-transfer-based protease activity assay and its use to monitor paralog-specific small ubiquitin-like modifier processing. Anal. Biochem. 2007, 363:83-90.
215. Bischof O., Dejean A. SUMO is growing senescent. Cell Cycle 2007, 6:677-681.
216. Gutierrez G.J., Ronai Z. Ubiquitin and SUMO systems in the regulation of mitotic checkpoints. Trends Biochem. Sci. 2006, 31:324-332.
217. Meinecke I., Cinski A., Baier A., Peters M.A., Dankbar B., Wille A., Drynda A., Mendoza H., Gay R.E., Hay R.T., Ink B., Gay S., Pap T. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc Natl Acad Sci U S A 2007, 104:5073-5078.
218. Melchior F., Hengst L. SUMO-1 and p53. Cell Cycle 2002, 1:245-249.
219. Eloranta J.J., Hurst H.C. Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo. J. Biol. Chem. 2002, 277:30798-30804.
220. Williams T., Tjian R. Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. Genes Dev. 1991, 5:670-682.
221. Bies J., Markus J., Wolff L. Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J. Biol. Chem. 2002, 277:8999-9009.
222. Comerford K.M., Leonard M.O., Karhausen J., Carey R., Colgan S.P., Taylor C.T. Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia. Proc Natl Acad Sci U S A 2003, 100:986-991.
223. Degerny C., Monte D., Beaudoin C., Jaffray E., Portois L., Hay R.T., de Launoit Y., Baert J.L. SUMO modification of the Ets-related transcription factor ERM inhibits its transcriptional activity. J. Biol. Chem. 2005, 280:24330-24338.
224. Ji Z., Degerny C., Vintonenko N., Deheuninck J., Foveau B., Leroy C., Coll J., Tulasne D., Baert J.L., Fafeur V. Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation. Oncogene 2007, 26:395-406.
225. Chun T.H., Itoh H., Subramanian L., Iniguez-Lluhi J.A., Nakao K. Modification of GATA-2 transcriptional activity in endothelial cells by the SUMO E3 ligase PIASy. Circ. Res. 2003, 92:1201-1208.
226. Kishi A., Nakamura T., Nishio Y., Maegawa H., Kashiwagi A. Sumoylation of Pdx1 is associated with its nuclear localization and insulin gene activation. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E830-E840.
227. Ross S., Best J.L., Zon L.I., Gill G. SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol. Cell. 2002, 10:831-842.
228. Ungureanu D., Vanhatupa S., Kotaja N., Yang J., Aittomaki S., Janne O.A., Palvimo J.J., Silvennoinen O. PIAS proteins promote SUMO-1 conjugation to STAT1. Blood 2003, 102:3311-3313.
229. Chakrabarti S.R., Sood R., Ganguly S., Bohlander S., Shen Z., Nucifora G. Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9. Proc Natl Acad Sci U S A 1999, 96:7467-7472.
230. Chakrabarti S.R., Sood R., Nandi S., Nucifora G. Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies. Proc Natl Acad Sci U S A 2000, 97:13281-13285.
231. Wu Q., Lin X.F., Ye X.F., Zhang B., Xie Z., Su W.J. Ubiquitinated or sumoylated retinoic acid receptor alpha determines its characteristic and interacting model with retinoid X receptor alpha in gastric and breast cancer cells. J. Mol. Endocrinol. 2004, 32:595-613.
232. Xu X., Vatsyayan J., Gao C., Bakkenist C.J., Hu J. Sumoylation of eIF4E activates mRNA translation. EMBO Rep. 2010, 11:299-304.
233. Bischof O., Schwamborn K., Martin N., Werner A., Sustmann C., Grosschedl R., Dejean A. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol. Cell. 2006, 22:783-794.
234. David G., Neptune M.A., DePinho R.A. SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J. Biol. Chem. 2002, 277:23658-23663.
235. Ythier D., Larrieu D., Binet R., Binda O., Brambilla C., Gazzeri S., Pedeux R. Sumoylation of ING2 regulates the transcription mediated by Sin3A. Oncogene 2010, 29:5946-5956.
236. Kim J.H., Lee J.M., Nam H.J., Choi H.J., Yang J.W., Lee J.S., Kim M.H., Kim S.I., Chung C.H., Kim K.I., Baek S.H. SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells. Proc Natl Acad Sci U S A 2007, 104:20793-20798.
237. Chen C.Y., Fang H.Y., Chiou S.H., Yi S.E., Huang C.Y., Chiang S.F., Chang H.W., Lin T.Y., Chiang I.P., Chow K.C. Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. Cancer Sci. 2011, 102:1582-1589.
238. Moschos S.J., Jukic D.M., Athanassiou C., Bhargava R., Dacic S., Wang X., Kuan S.F., Fayewicz S.L., Galambos C., Acquafondata M., Dhir R., Becker D. Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum. Pathol. 2010, 41:1286-1298.